Vor Biopharma (NASDAQ:VOR) Rating Increased to Hold at Zacks Research

Key Points

• Vor Biopharma has been upgraded by Zacks Research from a "strong sell" to a "hold" rating, reflecting a more positive outlook on the company's stock.
• The company reported a significant earnings miss for the last quarter, with an EPS of ($2.18), falling short of the consensus estimate of ($0.57) by ($1.61).
• Vor Biopharma specializes in developing engineered hematopoietic stem cell therapies for cancer treatment, particularly with its candidate VOR33 targeting acute myeloid leukemia (AML).

Vor Biopharma (NASDAQ:VOR - Get Free Report) was upgraded by equities research analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a research note issued on Wednesday, September 10th,Zacks.com reports.

Several other research analysts also recently issued reports on the company. Wall Street Zen downgraded Vor Biopharma to a "strong sell" rating in a research report on Saturday, June 28th. HC Wainwright raised Vor Biopharma from a "hold" rating to a "strong-buy" rating in a report on Monday, June 30th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy".

Vor Biopharma Stock Performance

Shares of VOR stock traded down $0.08 during mid-day trading on Wednesday, reaching $1.50. The stock had a trading volume of 3,795,496 shares, compared to its average volume of 7,583,651. The firm has a market capitalization of $189.39 million, a P/E ratio of -0.11 and a beta of 2.05. Vor Biopharma has a 12-month low of $0.13 and a 12-month high of $3.29. The firm's 50-day moving average is $2.08.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($2.18) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by ($1.61).

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.